Vector-mediated cancer gene therapy: An overview

Cancer Biology and Therapy

Volumn 4, Issue 5, 2005, Pages 512-517

  Seth, Prem ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adenovirus; Anti angiogenesis; Anti oncogenes; Cancer gene therapy; Immunomodulation; Lenti virus; Metastasis; Retrovirus; Suicide genes; Targetable vectors; Tumor suppressors

Indexed keywords

ADENOVIRUS VECTOR; ANTIINFECTIVE AGENT; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; IFOSFAMIDE; OXAZAPHOSPHORINE; PACLITAXEL; RETROVIRUS VECTOR;

ANGIOGENESIS; CANCER INVASION; CARCINOGENESIS; CELL PROTECTION; GENE TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOMODULATION; METASTASIS; MOLECULE; ONCOGENE; POXVIRUS; RADIOSENSITIZATION; REVIEW; STEM CELL; SUICIDE GENE; TUMOR SUPPRESSOR GENE;

EID: 24144480780     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.5.1705     Document Type: Review

References (59)

1. Larin SS, Georgiev GP, Kiselev SL. Gene transfer approaches in cancer immunotherapy. Gene Ther 2004; 11:S18-25.
2. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 2004; 101:14567-71.
3. McCormick F. Cancer gene therapy: Fringe or cutting edge? Nat Rev Cancer 2001; 1:130-41.
4. Fang B, Roth JA. The role of gene therapy in combined modality treatment strategies for cancer. Curr Opin Mol Ther 2003; 5:475-82.
5. Roth JA, Grammer SF. Tumor suppressor gene therapy. Methods Mol Biol 223:577-98.
6. Wadhwa PD, Zielske SP, Roth JC, Ballas CB, Bowman JE, Gerson SL. Cancer gene therapy: Scientific basis. Annu Rev Med 2002; 53:437-52.
7. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789-99.
8. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev 2004; 18:2315-35.
9. Weir B, Zhao X, Meyerson M. Somatic alterations in the human cancer genome. Cancer Cell 2004; 6:433-8.
10. Nishizaki M, Fujiwara T, Tanida T, Hizuta A, Nishimori H, Tokino T, Nakamura Y, Bouvet M, Roth JA, Tanaka N. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: A proposed mechanism for bystander effect. Clin Cancer Res 1999; 5:1015-1023.
11. Seth P. Preclinical studies with tumor suppressor genes. Adv Exp Med Biol 2000; 465:183-92.
12. Niculescu-Duvaz I, Springer CJ. Introduction to the background, principles, and state of the art in suicide gene therapy. Methods Mol Med 2004; 90:1-27.
13. McKeown SR, Ward C, Robson T. Gene-directed enzyme prodrug therapy: A current assessment. Curr Opin Mol Ther 2004; 6:421-35.
14. Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet 2003; 33:238-44.
15. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004; 350:1461-3.
16. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-8.
17. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411:375-9.
18. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7.
19. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003; 22:7486-95.
20. Gridley DS, Slater JM. Combining gene therapy and radiation against cancer. Curr Gene Ther 2004; 4:231-48.
21. Sah NK, Munshi A, Nishikawa T, Mukhopadhyay T, Roth JA, Meyn RE. Adenovirus-mediated wild-type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity. Mol Cancer Ther 2003; 2:1223-31.
22. Wang SC, Zhang L, Hortobagyi GN, Hung MC. Targeting HER2: Recent developments and future directions for breast cancer patients. Semin Oncol 2001; 28:21-9.
23. Sorrentino BP. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat Rev Cancer 2002; 2:431-41.
24. Bollard CM, Heslop HE, Brenner MK. Gene-marking studies of hematopoietic cells. Int J Hematol 2001; 73:14-22.
25. Buchschacher Jr GL. Introduction to retroviruses and retroviral vectors. Somat Cell Mol Genet 2001; 26:1-11.
26. Ward M, Sattler R, Grossman IR, Bell Jr AJ, Skerrett D, Baxi L, Bank A. A stable murine-based RD114 retroviral packaging line efficiently transduces human hematopoietic cells. Mol Ther 2003; 8:804-12.
27. Hlavaty J, Stracke A, Klein D, Salmons B, Gunzburg WH, Renner M. Multiple modifications allow high-titer production of retroviral vectors carrying heterologous regulatory elements. J Virol 2004; 78:1384-92.
28. Kohn DB, Sadelain M, Dunbar C, Bodine D, Kiem HP, Candotti F, Tisdale J, Riviere I, Blau CA, Richard RE, Sorrentino B, Nolta J, Malech H, Brenner M, Cornetta K, Cavagnaro J, High K, Glorioso J. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 2003; 8:180-7.
29. Seth P. Adenoviruses: Basic Biology to Gene Therapy. Austin, TX: R G Landes Company, 1999:1-314.
30. Seth P. Adenoviral vectors. Adv Exp Med Biol 2000; 465:13-22.
31. Hitt MM, Graham FL. Adenovirus vectors for human gene therapy. Adv Virus Res 2000; 55:479-505.
32. Imperiale MJ, Kochanek S. Adenovirus vectors: Biology, design, and production. Curr Top Microbiol Immunol 2004; 273:335-57.
33. Roy-Chowdhury J, Horwitz MS. Evolution of adenoviruses as gene therapy vectors. Mol Ther 2002; 5:340-4.
34. Cabo II. Immunology and gene therapy. Mol Ther 2002; 5:486-91.
35. McCarty DM, Young SM, Samulski RJ. Integration of Adeno-Associated Virus (Aav) and Recombinant Aav Vectors. Annu Rev Genet 2004; 38:819-45.
36. Linden RM, Berns KI. Molecular biology of adeno-associated viruses. Contrib Microbiol 2000; 4:68-84.
37. Guo ZS, Bartlett DL. Vaccinia as a vector for gene delivery. Expert Opin Biol Ther 2004; 4:901-17.
38. Kwak H, Horig H, Kaufman HL. Poxviruses as vectors for cancer immunotherapy. Curr Opin Drug Discov Devel 2003; 6:161-8.
39. Goins WF, Wolfe D, Krisky DM, Bai Q, Burton EA, Fink DJ, Glorioso JC. Delivery using herpes simplex virus: An overview. Methods Mol Biol 2004; 246:257-99.
40. Oehmig A, Fraefel C, Breakefield XO. Update on herpesvirus amplicon vectors. Mol Ther 2004; 10:630-43.
41. Gummuluru S, Emerman M. Advances in HIV molecular biology. Aids 2002; 16:S17-23.
42. Galimi F, Verma IM. Opportunities for the use of lentiviral vectors in human gene therapy. Curr Top Microbiol Immunol 2002; 261:245-54.
43. Felgner PL. Nonviral strategies for gene therapy. Sci Am 1997; 276:102-6.
44. Liu F, Shollenberger LM, Huang L. Nonimmunostimulatory nonviral vectors. Faseb J 2004; 18:1779-81.
45. Li W, Nicol F, Szoka Jr FC. GALA: A designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv Drug Deliv Rev 2004; 56:967-985.
46. Wells DJ. Gene therapy progress and prospects: Electroporation and other physical methods. Gene Ther 2004; 11:1363-9.
47. Joshee N, Bastola DR, Cheng PW. Transferrin-facilitated lipofection gene delivery strategy: Characterization of the transfection complexes and intracellular trafficking. Hum Gene Ther 2002; 13:1991-2004.
48. Lanciotti J, Song A, Doukas J, Sosnowski B, Pierce G, Gregory R, Wadsworth S, O'Riordan C. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther 2003; 8:99-107.
49. Barrette S, Douglas J, Orlic D, Anderson SM, Seidel NE, Miller AD, Bodine DM. Superior transduction of mouse hematopoietic stem cells with 10A1 and VSV-G pseudotyped retrovirus vectors. Mol Ther 2000; 1:330-8.
50. Weitzman MD, Young Jr SM, Cathomen T, Samulski RJ. Targeted integration by adeno-associated virus. Methods Mol Med 2003; 76:201-19.
51. Sandrin V, Russell SJ, Cosset FL. Targeting retroviral and lentiviral vectors. Curr Top Microbiol Immunol 2003; 281:137-78.
52. Robson T, Hirst DG. Transcriptional targeting in cancer gene therapy. J Biomed Biotechnol 2003; 110-37.
53. Saukkonen K, Hemminki A. Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther 2004; 4:683-966.
54. Kloeckner J, Prasmickaite L, Hogset A, Berg K, Wagner E. Photochemically enhanced gene delivery of EGF receptor-targeted DNA polyplexes. J Drug Target 2004; 12:205-13.
55. Ogris M, Walker G, Blessing T, Kircheis R, Wolschek M, Wagner E. Tumor-targeted gene therapy: Strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J Control Release 2003; 91:173-81.
56. Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ. The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med 2002; 8:S68-73.
57. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4:346-58.
58. Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol 2003; 21:117-22.
59. Shah K. Current advances in molecular imaging of gene and cell therapy for cancer. Cancer Biol Ther 2005; 4:518-23.